CN105189756B - 具有沉默突变的重组rsv、其相关疫苗和方法 - Google Patents

具有沉默突变的重组rsv、其相关疫苗和方法 Download PDF

Info

Publication number
CN105189756B
CN105189756B CN201480025415.2A CN201480025415A CN105189756B CN 105189756 B CN105189756 B CN 105189756B CN 201480025415 A CN201480025415 A CN 201480025415A CN 105189756 B CN105189756 B CN 105189756B
Authority
CN
China
Prior art keywords
rsv
gene
sequence
certain embodiments
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480025415.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105189756A (zh
Inventor
马丁·L·摩尔
佳·孟
安妮·霍泰德
伊丽莎白·利陶尔
克里斯多佛·斯托巴特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Childrens Healthcare of Atlanta Inc
Original Assignee
Emory University
Childrens Healthcare of Atlanta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, Childrens Healthcare of Atlanta Inc filed Critical Emory University
Priority to CN202110603289.6A priority Critical patent/CN113322264B/zh
Publication of CN105189756A publication Critical patent/CN105189756A/zh
Application granted granted Critical
Publication of CN105189756B publication Critical patent/CN105189756B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201480025415.2A 2013-03-14 2014-03-14 具有沉默突变的重组rsv、其相关疫苗和方法 Active CN105189756B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110603289.6A CN113322264B (zh) 2013-03-14 2014-03-14 具有沉默突变的重组rsv、其相关疫苗和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781228P 2013-03-14 2013-03-14
US61/781,228 2013-03-14
US201361890500P 2013-10-14 2013-10-14
US61/890,500 2013-10-14
PCT/US2014/027447 WO2014152534A1 (en) 2013-03-14 2014-03-14 Recombinant rsv with silent mutations, vaccines, and methods related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110603289.6A Division CN113322264B (zh) 2013-03-14 2014-03-14 具有沉默突变的重组rsv、其相关疫苗和方法

Publications (2)

Publication Number Publication Date
CN105189756A CN105189756A (zh) 2015-12-23
CN105189756B true CN105189756B (zh) 2021-06-11

Family

ID=51581238

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480025415.2A Active CN105189756B (zh) 2013-03-14 2014-03-14 具有沉默突变的重组rsv、其相关疫苗和方法
CN202110603289.6A Active CN113322264B (zh) 2013-03-14 2014-03-14 具有沉默突变的重组rsv、其相关疫苗和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110603289.6A Active CN113322264B (zh) 2013-03-14 2014-03-14 具有沉默突变的重组rsv、其相关疫苗和方法

Country Status (8)

Country Link
US (4) US10232032B2 (enExample)
EP (2) EP2970981B1 (enExample)
JP (4) JP6506249B2 (enExample)
CN (2) CN105189756B (enExample)
AU (3) AU2014239583B2 (enExample)
ES (1) ES2854673T3 (enExample)
PL (1) PL2970981T3 (enExample)
WO (1) WO2014152534A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2854673T3 (es) 2013-03-14 2021-09-22 Univ Emory VSR recombinante con mutaciones silenciosas, vacunas y métodos relacionados con ello
WO2017075125A1 (en) * 2015-10-29 2017-05-04 Emory University Chimeric RSV, Immunogenic Compositions, and Methods of Use
EP3439672B1 (en) 2016-04-05 2020-11-25 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
IL264119B2 (en) * 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
WO2019162532A1 (en) * 2018-02-26 2019-08-29 Stiftung Tierärztliche Hochschule Hannover (Tiho) Improved pneumovirus reverse genetics
MX2021005607A (es) * 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
US20220125909A1 (en) * 2019-02-11 2022-04-28 Emory University Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use
CA3211412A1 (en) * 2021-04-08 2022-10-13 Codagenix Inc. Method of eliciting an immune response against respiratory syncytial virus
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof
US20240082385A1 (en) * 2022-05-27 2024-03-14 Meissa Vaccines, Inc. Rsv vaccines and methods of administering same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118530A1 (en) * 2004-10-08 2008-05-22 Kew Olen M Modulation of Replicative Fitness By Deoptimization of Synonymous Codons
WO2008121992A2 (en) * 2007-03-30 2008-10-09 Research Foundation Of State University Of New York Attenuated viruses useful for vaccines
CN102272295A (zh) * 2008-11-05 2011-12-07 默沙东公司 活减毒呼吸道合胞病毒

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
WO2001089562A1 (en) 2000-05-25 2001-11-29 Medimmune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
AU2004226369A1 (en) 2003-03-28 2004-10-14 Medimmune, Llc Compositions and methods involving respiratory syncytial virus subgroup B strain 9320
EP1699919B1 (en) 2003-12-24 2017-01-11 De Staat der Nederlanden, Vertegenwoordigd Door de Minister Van Volksgezondheid, Welzijn en Sport A respiratory syncytial virus with a genomic deficiency complemented in trans
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
HRP20160859T1 (hr) * 2008-12-09 2016-09-23 Novavax, Inc. Modificirani proteini rsv f i postupci njihove upotrebe
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
CA2840982C (en) 2011-07-06 2022-06-07 Vira BITKO Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
ES2952387T3 (es) * 2013-02-08 2023-10-31 Us Health Atenuación del virus respiratorio sincitial humano mediante la desoptimización de pares de codones a escala genómica
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
ES2854673T3 (es) 2013-03-14 2021-09-22 Univ Emory VSR recombinante con mutaciones silenciosas, vacunas y métodos relacionados con ello
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
WO2017075125A1 (en) 2015-10-29 2017-05-04 Emory University Chimeric RSV, Immunogenic Compositions, and Methods of Use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118530A1 (en) * 2004-10-08 2008-05-22 Kew Olen M Modulation of Replicative Fitness By Deoptimization of Synonymous Codons
WO2008121992A2 (en) * 2007-03-30 2008-10-09 Research Foundation Of State University Of New York Attenuated viruses useful for vaccines
CN102272295A (zh) * 2008-11-05 2011-12-07 默沙东公司 活减毒呼吸道合胞病毒

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A 型流感病毒NS1 基因密码子去优化改造引起病毒毒力减弱;栾世家等;《生物工程学报》;20090525;第25卷(第5期);720-726 *
Deletion of nonstructural proteins NS1 and NS2 from Pneumonia Virus of mice attenuates Viral Replication and reduces pulmonary cytokine expression and disease.;U.J.BUCHHOLZ等;《JOURNAL OF VIROLOGY》;20090215;第83卷(第4期);1969-1980 *
Effects of nonstructural proteins NS1 and NS2 of human Resporatiory Syncytial Virus on interferon regulatory factor 3,NF-B,and proinflammatory cytokines.;K.M.SPANN等;《JOURNAL OF VIROLOGY》;20050501;第79卷(第9期);5353-5362 *
Identifivation of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus.;Tolley K P等;《VACCINE》;19961201;第14卷(第17期);1637-1646 *
U39661;Respiratory syncytial virus;《EMBL》;19970329 *

Also Published As

Publication number Publication date
AU2023206177A1 (en) 2023-08-10
CN113322264A (zh) 2021-08-31
JP2016513471A (ja) 2016-05-16
EP2970981A1 (en) 2016-01-20
EP2970981B1 (en) 2020-10-28
US20160030549A1 (en) 2016-02-04
JP2022023054A (ja) 2022-02-07
JP6506249B2 (ja) 2019-04-24
CN113322264B (zh) 2024-05-31
EP2970981A4 (en) 2017-02-22
AU2020244533B2 (en) 2023-04-20
HK1218428A1 (zh) 2017-02-17
AU2020244533A1 (en) 2020-10-29
US20230302115A1 (en) 2023-09-28
EP3798310A1 (en) 2021-03-31
JP6956965B2 (ja) 2021-11-02
US10792356B2 (en) 2020-10-06
CA2906606A1 (en) 2014-09-25
JP2019115356A (ja) 2019-07-18
US12186386B2 (en) 2025-01-07
ES2854673T3 (es) 2021-09-22
US20190224306A1 (en) 2019-07-25
WO2014152534A1 (en) 2014-09-25
JP7239948B2 (ja) 2023-03-15
AU2014239583A1 (en) 2015-10-15
US20210100893A1 (en) 2021-04-08
JP2023062157A (ja) 2023-05-02
AU2014239583B2 (en) 2020-07-02
PL2970981T3 (pl) 2021-07-05
US10232032B2 (en) 2019-03-19
CN105189756A (zh) 2015-12-23
US11471524B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
US12186386B2 (en) Recombinant RSV with silent mutations, vaccines, and methods related thereto
US12257296B2 (en) Chimeric RSV, immunogenic compositions, and methods of use
US10227569B2 (en) Respiratory syncytial virus expression vectors
US20220125909A1 (en) Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use
US20240082385A1 (en) Rsv vaccines and methods of administering same
CA2906606C (en) Recombinant rsv with silent mutations, vaccines, and methods related thereto
HK1218428B (zh) 具有沉默突变的重组rsv、其相关疫苗和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1218428

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment